Deoxycoformycin (pentostatin) in the treatment of splenic marginal zone lymphoma (SMZL) with or without villous lymphocytes

European Journal of Haematology

Volumn 75, Issue 2, 2005, Pages 130-135

  Iannitto, Emilio ^a,b   Minardi, Viviana ^a   Calvaruso, Giuseppina ^a   Ammatuna, Emanuele ^a   Florena, Ada Maria ^a   Mulè, Antonino ^a   Tripodo, Claudio ^a   Quintini, Gerlando ^a   Abbadessa, Vincenzo ^a  

^a UNIVERSITY OF PALERMO   (Italy)

^b UNIVERSITY OF PALERMO   (Italy)

Author keywords

NHL; Pentostatin; Purine analogues; SLVL; Splenic lymphoma

Indexed keywords

PENTOSTATIN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CYTOPENIA; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; LIVER TOXICITY; LYMPHOCYTE; LYMPHOMA; MALE; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SPLEEN MARGINAL ZONE LYMPHOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADULT; AGED; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; LYMPHOCYTES; LYMPHOMA, MUCOSA-ASSOCIATED LYMPHOID TISSUE; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; PENTOSTATIN; REMISSION INDUCTION; SPLENIC NEOPLASMS; SURVIVAL ANALYSIS;

EID: 22444449151     PISSN: 09024441     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0609.2005.00426.x     Document Type: Article

References (24)

1. ISAACSON PG. Splenic marginal zone lymphoma. In: JAFFE ES, HARRIS NL, STEIN H, VARDIMAN JW, eds. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC, 2001; 135-137.
2. FRANCO V, FLORENA AM, IANNITTO E. Splenic marginal zone lymphoma. Blood 2003;101:2464-2472.
3. CATOVSKY D, MATUTES E. Splenic lymphoma with circulating villous lymphocytes/splenic marginal-zone lymphoma. Semin Hematol 1999;36:148-154.
4. TROUSSARD X, VALENSI F, DUCHAYNE E, et al. Splenic lymphoma with villous lymphocytes: clinical presentation, biology and prognostic factors in a series of 100 patients. Br J Haematol 1996;93:731-736.
5. THIEBLEMONT C, FELMAN P, BERGER F, et al. Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients. Clin Lymph 2002;3:41-47.
6. VIRCHIS A, MEHTA A. Splenic lymphoma with villous lymphocytes (SLVL) responding to 2-chlorodeoxyadenosine (2-CdA). Br J Haematol 1998;100:609.
7. LEFRERE F, HERMINE O, FRANCOIS S, et al. Lack of efficacy of 2-chlorodeoxyadenoside in the treatment of splenic lymphoma with villous lymphocytes. Leuk Lymphoma 2000;40:113-7.
8. RICCIONI R, CARACCIOLO F, GALIMBERTI S, CECCONI N, PETRINI M. Low dose 2-CdA schedule activity in splenic marginal zone lymphomas. Hematol Oncol 2003;21:163-168.
9. BOLAM S, ORCHARD J, OSCIER D. Fludarabine is effective in the treatment of splenic lymphoma with villous lymphocytes. Br J Haematol 1997;99:158-161.
10. LEFRERE F, LEVY V, FRANCOIS S, et al. Fludarabine therapy in patients with splenic lymphoma with villous lymphocytes: an update. Leukemia 2004;18:1924-1925.
11. DEARDEN CE, MATUTES E, CATOVSKY D. Clinical overview of pentostatin (Nipent) use in lymphoid malignancies. Semin Oncol 2000;27:22-6.
12. (R)) in the treatment of chronic lymphocyte leukemia and hairy cell leukemia. Expert Rev Antic Ther 2004;4:27-36.
13. KAPLAN EL, MEIER P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-481.
14. MALOISEL F, BENBOUBKER L, GARDEMBAS M, et al. Long-term outcome with pentostatine treatment in hairy cell leukmia patients. A French retrospective study of 238 patients. Leukemia 2003;17:45-51.
15. RAFEL M, CERVANTES F, BELTRAM JM, et al. Deoxycoformycin in the treatment of patients with hairy cell leukemia: results of a Spanish collaborative study of 80 patients. Cancer 2000;88:352-357.
16. THIEBLEMONT C, FELMAN P, CALLET-BAUCHU E, et al. Splenic marginal-zone lymphoma: a distinct clinical and pathological entity. Lancet Oncol 2003;4:95-103.
17. FRANCO V, FLORENA AM, ASCANI S, et al. CD27 distinguishes two phases in bone marrow infiltration of splenic marginal zone lymphoma. Histopathology 2004;44:381-386.
18. FRANCO V, FLORENA AM, STELLA M, RIZZO A, IANNITTO E, QUINTINI, G. CAMPESI G. Splenectomy influences bone marrow infiltration in patients with splenic marginal zone cell lymphoma with or without villous lymphocytes. Cancer 2001;91:294-301.
19. PARRY-JONES N, MATUTES E, GRUSZKA-WESTWOOD AM, et al. Prognostic features of splenic lymphoma with villous lymphocytes: a report on 129 cases. Br J Haematol 2003;120:759-764.
20. IANNITTO E, AMBROSETTI A, AMMATUNA E, et al. Splenic marginal zone lymphoma with or without villous lymphocytes. Cancer 2004;101:2050-2057.
21. HERMINE O, LEERERE F, BRONOWICKI J-P, et al. Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. N Engl J Med 2002;347:89-94.
22. THOMAS DA, O'BRIEN S, CORTES J, et al. Treatment of splenic Lymphoma with villous lymphocytes (SLVL) and marginal zone lymphomas (MZL) with single agent rituximab. Blood 2001;98:134a (abstract).
23. ARCAINI L, ORLANDI E, SCOTTI M, et al. Combination of Rituximab, cyclophosphamide and Vincristine induces complete haematologic remission of splenic marginal zone lymphoma. Clin Lymph 2004;4:250-252.
24. SHARMA K, DAVE HP, SIEGEL RS, et al. Rituximab for treatment of Splenic Lymphoma with villous lymphocytes. Blood 2003;102(Suppl. 1) abstr:4954.